Macrophage Distribution Affected by Virus-Encoded Granulocyte Macrophage Colony Stimulating Factor Combined with Lactate Oxidase

Hsieh, Chia-Chen; Hsieh, Ming-Jung; Wang, Yu-Hsin; Liao, Zi-Xian

doi:10.1021/acsomega.2c03213

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, granulocyte-macrophage colony-stimulating factor combined with LOx could have a synergistic effect on regulating macrophage distribution to enhance cancer treatment as an improved viral therapy. [52] As described previously, lactate contributes to tumor growth and metastasis, suggesting that targeting lactate is a promising anticancer therapy. LOx specifically consumes lactate, and the process consumes O 2 and produces pyruvate and H 2 O 2 , which are limited by the hypoxic TME.…”

Section: Other Multimodal Synergistic Therapymentioning

confidence: 75%

See 1 more Smart Citation

Lactate‐Oxidase‐Instructed Cancer Diagnosis and Therapy

et al. 2023

View full text Add to dashboard Cite

Lactate oxidase (LOx) has attracted extensive interest in cancer diagnosis and therapy in recent years owing to its specific catalysis on l‐lactate; its catalytic process consumes oxygen (O2) and generates a large amount of hydrogen peroxide (H2O2) and pyruvate. Given high levels of lactate in tumor tissues and its tight correlation with tumor growth, metastasis, and recurrence, LOx‐based biosensors including H2O2‐based, O2‐based, pH‐sensitive, and electrochemical have been designed for cancer diagnosis, and various LOx‐based cancer therapy strategies including lactate‐depletion‐based metabolic cancer therapy/immunotherapy, hypoxia‐activated chemotherapy, H2O2‐based chemodynamic therapy, and multimodal synergistic cancer therapy have also been developed. In this review, the lactate‐specific catalytic properties of LOx are introduced, and the recent advances on LOx‐instructed cancer diagnostic or therapeutic platforms and corresponding biological applications are summarized. Additionally, the challenges and potential of LOx‐based nanomedicines are highlighted.

show abstract

Section: Other Multimodal Synergistic Therapymentioning

confidence: 75%

“…Furthermore, granulocyte‐macrophage colony‐stimulating factor combined with LOx could have a synergistic effect on regulating macrophage distribution to enhance cancer treatment as an improved viral therapy. [ 52 ]…”

Section: Lox‐instructed Cancer Therapymentioning

confidence: 99%

Lactate‐Oxidase‐Instructed Cancer Diagnosis and Therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Furthermore, M2-type macrophages have been found to be more abundant in acidic tumor microenvironments [ 19 , 26 , 29 ]. Interestingly, we observed that ION treatment resulted in a significant reduction in the expression of CD206, a surface marker associated with M2-type macrophages, in RAW 264.7 M0 macrophages undergoing polarization and a notable increase in the expression of iNOS, a surface marker associated with M1-type macrophages [ 30 ]. These data show that ION incubation can modulate macrophage behavior, including their phenotype and polarization state [ 20 ].…”

Section: Resultsmentioning

confidence: 99%

Nano-modified viruses prime the tumor microenvironment and promote the photodynamic virotherapy in liver cancer

Ou,

Liao,

Kempson

et al. 2024

J Biomed Sci

Self Cite

View full text Add to dashboard Cite

Background As of 2020, hepatocellular carcinoma (HCC), a form of liver cancer, stood as the third most prominent contributor to global cancer-related mortality. Combining immune checkpoint inhibitors (ICI) with other therapies has shown promising results for treating unresectable HCC, offering new opportunities. Recombinant adeno-associated viral type 2 (AAV2) virotherapy has been approved for clinical use but it efficacy is stifled through systemic administration. On the other hand, iron oxide nanoparticles (ION) can be cleared via the liver and enhance macrophage polarization, promoting infiltration of CD8+ T cells and creating a more favorable tumor microenvironment for immunotherapy. Methods To enhance the efficacy of virotherapy and promote macrophage polarization towards the M1-type in the liver, ION-AAV2 were prepared through the coupling of ION-carboxyl and AAV2-amine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)/N-hydroxysulfosuccinimide (Sulfo-NHS). Efficacy after systemic delivery of ION-AAV2 in an orthotopic HCC model was evaluated. Results After 28 days, the tumor weight in mice treated with ION-AAV2 was significantly reduced by 0.56-fold compared to the control group. The ION-AAV2 treatment led to an approximate 1.80-fold increase in the level of tumor associated M1-type macrophages, while the number of M2-type macrophages was reduced by 0.88-fold. Moreover, a proinflammatory response increased the population of tumor-infiltrating CD8+ T cells in the ION-AAV2 group. This transformation converted cold tumors into hot tumors. Conclusions Our findings suggest that the conjugation of ION with AAV2 could be utilized in virotherapy while simultaneously exploiting macrophage-modulating cancer immunotherapies to effectively suppress HCC growth.

show abstract

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Lecoultre,

Walker,

El Helali

2024

Clin Exp Med

View full text Add to dashboard Cite

Oncolytic viruses (OV) are a promising strategy in cancer immunotherapy. Their capacity to promote anti-tumoral immunity locally raises hope that cancers unresponsive to current immunotherapy approaches could be tackled more efficiently. In this context, tumor-associated macrophages (TAM) must be considered because of their pivotal role in cancer immunity. Even though TAM tend to inhibit anti-tumoral responses, their ability to secrete pro-inflammatory cytokines and phagocytose cancer cells can be harnessed to promote therapeutic cancer immunity. OVs have the potential to promote TAM pro-inflammatory functions that favor anti-tumoral immunity. But in parallel, TAM pro-inflammatory functions induce OV clearance in the tumor, thereby limiting OV efficacy and highlighting that the interaction between OV and TAM is a double edge sword. Moreover, engineered OVs were recently developed to modulate specific TAM functions such as phagocytic activity. The potential of circulating monocytes to deliver OV into the tumor after intravenous administration is also emerging. In this review, we will present the interaction between OV and TAM, the potential of engineered OV to modulate specific TAM functions, and the promising role of circulating monocytes in OV delivery to the tumor.

show abstract

Macrophage Distribution Affected by Virus-Encoded Granulocyte Macrophage Colony Stimulating Factor Combined with Lactate Oxidase

Cited by 5 publications

References 21 publications

Lactate‐Oxidase‐Instructed Cancer Diagnosis and Therapy

Lactate‐Oxidase‐Instructed Cancer Diagnosis and Therapy

Nano-modified viruses prime the tumor microenvironment and promote the photodynamic virotherapy in liver cancer

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Contact Info

Product

Resources

About